Dashboard
Manage Tickers

ABBV AbbVie Inc.

NYSE abbvie.com


$ 235.45 $ 0.77 (0.33 %)    

Tuesday, 18-Nov-2025 13:57:13 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 599.77 $ 0.15 (0.03 %)
DIA $ 463.05 $ 0.89 (0.19 %)
SPY $ 663.35 $ 1.22 (0.18 %)
TLT $ 88.93 $ -0.42 (-0.47 %)
GLD $ 374.70 $ -0.15 (-0.04 %)
$ 234
$ 234.03
$ 235.64 x 140
$ 235.70 x 6
$ 233.34 - $ 237.19
$ 158.28 - $ 243.06
5,023,149
na
413.57B
$ 0.42
$ 173.19
TBD
na
na ($ 0.03)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-04-2025 09-30-2025 10-Q
2 08-04-2025 06-30-2025 10-Q
3 05-09-2025 03-31-2025 10-Q
4 02-14-2025 12-31-2024 10-K
5 11-04-2024 09-30-2024 10-Q
6 08-07-2024 06-30-2024 10-Q
7 05-03-2024 03-31-2024 10-Q
8 02-20-2024 12-31-2023 10-K
9 11-06-2023 09-30-2023 10-Q
10 08-07-2023 06-30-2023 10-Q
11 05-05-2023 03-31-2023 10-Q
12 02-17-2023 12-31-2022 10-K
13 11-04-2022 09-30-2022 10-Q
14 08-04-2022 06-30-2022 10-Q
15 05-06-2022 03-31-2022 10-Q
16 02-18-2022 12-31-2021 10-K
17 11-02-2021 09-30-2021 10-Q
18 08-02-2021 06-30-2021 10-Q
19 05-07-2021 03-31-2021 10-Q
20 02-19-2021 12-31-2020 10-K
21 11-04-2020 09-30-2020 10-Q
22 08-04-2020 06-30-2020 10-Q
23 05-08-2020 03-31-2020 10-Q
24 02-21-2020 12-31-2019 10-K
25 11-06-2019 09-30-2019 10-Q
26 08-05-2019 06-30-2019 10-Q
27 05-03-2019 03-31-2019 10-Q
28 02-27-2019 12-31-2018 10-K
29 11-07-2018 09-30-2018 10-Q
30 08-07-2018 06-30-2018 10-Q
31 05-04-2018 03-31-2018 10-Q
32 02-16-2018 12-31-2017 10-K
33 11-07-2017 09-30-2017 10-Q
34 08-07-2017 06-30-2017 10-Q
35 05-05-2017 03-31-2017 10-Q
36 02-17-2017 12-31-2016 10-K
37 11-07-2016 09-30-2016 10-Q
38 08-05-2016 06-30-2016 10-Q
39 05-06-2016 03-31-2016 10-Q
40 02-19-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
AbbVie Secures FDA Approval For EPKINLY + ...
11/18/2025 17:51:04

-   EPKINLY plus rituximab and lenalidomide (EPKINLY + R2) is now the first and only bispecific antibody combination therapy av...

Core News & Articles
Live On CNBC, Josh Brown Hosts Segment Tit...
11/18/2025 17:40:59

Core News & Articles
FDA Approves Epcoritamab-bysp For Follicul...
11/18/2025 15:24:52

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-epcoritamab-bysp-follicular-lymphoma-indications<

a-look-into-abbvie-incs-price-over-earnings
A Look Into AbbVie Inc's Price Over Earnings
11/17/2025 21:00:53

abbvie-announces-new-6-month-45mg-lupron-depot-strength-receives-health-canada-approval-for-treatment-of-advanced-prostate-cancer
AbbVie Announces New 6-Month 45mg LUPRON D...
11/17/2025 12:04:51

LUPRON DEPOT (leuprolide acetate for extended-release injectable suspension) is a hormonal medication first approved by Health ...

10-health-care-stocks-with-whale-alerts-in-todays-session
10 Health Care Stocks With Whale Alerts In...
11/14/2025 17:35:28

abbvie-shares-rise-to-intraday-high-after-key-trading-signal
AbbVie Shares Rise To Intraday High After ...
11/12/2025 20:06:26

A key trading signal flashed for AbbVie shares at a price of $228.47, after which ABBV rose as much as 2.4% to an intraday high...

Core News & Articles
'AbbVie cuts ties with Google-backed longe...
11/12/2025 16:03:56

https://www.statnews.com/2025/11/12/abbvie-calico-layoffs/?utm_campaign=twitter_organic&utm_source=twitter&utm_medium=s...

abbvies-allergan-to-present-at-american-society-of-dermatologic-surgery-asds-annual-meeting-nov-13-16
AbbVie's Allergan To Present At American S...
11/12/2025 13:36:48

ubs-maintains-neutral-on-abbvie-raises-price-target-to-220
UBS Maintains Neutral on AbbVie, Raises Pr...
11/07/2025 16:15:42

UBS analyst Ashwani Verma maintains AbbVie (NYSE:ABBV) with a Neutral and raises the price target from $195 to $220.

100-invested-in-abbvie-5-years-ago-would-be-worth-this-much-today
$100 Invested In AbbVie 5 Years Ago Would ...
11/05/2025 20:45:42

piper-sandler-reiterates-overweight-on-abbvie-raises-price-target-to-289
Piper Sandler Reiterates Overweight on Abb...
11/05/2025 15:42:26

Piper Sandler analyst David Amsellem reiterates AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $284 t...

Core News & Articles
Calico Life Sciences Announces U.S. FDA Or...
11/05/2025 15:08:51

Calico Life Sciences LLC (Calico), a biotechnology organization focused on aging and age-related diseases and founded by Alphab...

citigroup-maintains-neutral-on-abbvie-lowers-price-target-to-235
Citigroup Maintains Neutral on AbbVie, Low...
11/03/2025 20:08:03

Citigroup analyst Geoff Meacham maintains AbbVie (NYSE:ABBV) with a Neutral and lowers the price target from $240 to $235.

what-the-options-market-tells-us-about-abbvie
What the Options Market Tells Us About AbbVie
11/03/2025 17:02:44

jp-morgan-maintains-overweight-on-abbvie-raises-price-target-to-260
JP Morgan Maintains Overweight on AbbVie, ...
11/03/2025 14:40:01

JP Morgan analyst Chris Schott maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $250 to $260.

looking-into-abbvie-incs-recent-short-interest
Looking Into AbbVie Inc's Recent Short Int...
10/31/2025 20:00:42

nasdaq-100-rebounds-amazon-jumps-10-on-strong-earnings-whats-moving-markets-friday
Nasdaq 100 Rebounds, Amazon Jumps 10% On S...
10/31/2025 17:26:36

Tech stocks edged higher Friday, rebounding from Thursday's 1.5% drop in the Nasdaq 100 as upbeat earnings from mega-cap gi...

abbvie-raises-2025-outlook-helped-by-strong-immunology-growth-boost-dividend
AbbVie Raises 2025 Outlook Helped By Stron...
10/31/2025 15:47:20

AbbVie beats Q3 estimates with $15.78 billion revenue, boosts dividend to $1.73, raises earnings outlook on strong drug portfol...

abbvie-executive-says-administrations-focus-on-achieving-greater-reductions-in-2027-medicare-drug-price-negotiation-round-was-clear-but-outcomes-will-not-impact-long-term-outlook
AbbVie Executive Says Administration's Foc...
10/31/2025 13:58:14

-Reuters

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION